Table 3. Tumor response rates for nivolumab treatment.

	Sunitinib	Pazopanib	p-value
	(n: 41)	(n: 34)
Complete response	1 (2%)	1 (3%)	0.925
Partial response	12 (28%)	18 (53%)	0.023
Objective response rate	13 (30%)	19 (56%)	0.028
Stable disease	11 (25%)	10 (29%)	0.715
Disease control rate	24 (55%)	29 (85%)	0.005
Progressive disease	20 (45%)	5 (15%)	0.005